



## Press release (Page 1/2)

### **Seventure confirms its European leadership in White Biotech Investments with its appointment to the German Cluster CLIB2021 Board**

Paris, France – March 12th 2008 – Seventure Partners is the first Venture Capital firm to become a board member of the German White Biotech Initiative CLIB2021, represented by its exclusive white biotech and chemical advisor, Larry Drumm.

Larry Drumm has more than 25 years of experience in white biotech and chemical industry, mainly in the US. He works as an exclusive consultant for Seventure Partners since 2003 as a growth advisor and white biotechnology business development expert.

Alongside to prestigious company positions/board memberships such as Evonik Industries, Bayer TS, Cognis, Henkel and LANXESS, Larry has been appointed to represent Seventure at CLIB2021 SAB – Strategic Advisory Board. “I am honoured to be part of this significant effort in white biotechnology” said Larry. He goes on to say “Germany is a real force in the chemical industry and this region of Germany is especially well positioned to impact the area of polymers and monomers as well as other parts of the chemical industry and targeted higher areas of the value chain.”

“We are particularly pleased to be represented by Larry on this CLIB2021 board” says Isabelle De Cremoux, General Partner and Director of Seventure Partners Life Sciences Department. “Our Life Sciences Department is very interested in white biotechnology and has invested in this area in several European countries, such as Metabolic Explorer in France and Fluxome Sciences in Denmark, where we were lead investor each time.” “Germany is of great interest to us because of its leadership in the worldwide chemical community and the potential impact industrial biotechnology in this and other industrial sectors. We have already invested in Berlin in Noxxon Pharma AG and are looking for more opportunities to invest in Germany.”



Entrepreneurs  
en capital



## Press release (Page 2/2)

### About Seventure Partners

Seventure Partners invests since 1997 in innovative businesses in ICT and Life Sciences. Seventure is a subsidiary of Natixis Private Equity, the asset management company of NatixisBanquePopulaire, which manages 3.1b€ in private equity investments. In Life Sciences, Seventure is more than a financial investor. We also bring to our portfolio companies a strong commitment to their growth, supported by our deep knowledge of the life science industry, our vision and entrepreneurial mindset, and our wide network all across Europe. We invest either in early or later stage companies and are usually lead or co-lead investor, though we can also act as a smart and active follower position in an international syndicate. We have over 500m€ under management.

### About CLIB2021

The association will foster the economic structure of industrial biotechnology by initiating trendsetting R&D strategies through its powerful network of industrial and academic stakeholders, commercial consumers as well as investors. Among the 32 founding members the chemical industry (Bayer TS, Cognis, Evonik Industries, Henkel, Lanxess), small and medium sized enterprises (SME) in the biotech area from all of Germany, academic institutes from Northrhine-Westfalia, engineering companies as well as business organisations and the chemical industry's association VCI NRW are combined. CLIB2021 stands for "Cluster Industrielle Biotechnologie". Further information can be found on [www.clib2021.com](http://www.clib2021.com)

### Contacts

- **Isabelle de Crémoux**  
Director of Life Sciences Dept, General Partner  
[isabelle.decremoux@seventure.fr](mailto:isabelle.decremoux@seventure.fr)  
Tel : +33 (0)1 58 19 22 77  
[www.seventure.fr](http://www.seventure.fr)

Private Equity *by* NPE : Entrepreneurs in Private Equity

A leader in private equity for small and mid-sized companies in France, Natexis Private Equity is developing a range of products tailored to the needs of entrepreneurs and investors by forming the best investment teams sharing a common vision. The **Private Equity by NPE** label covers 16 teams and over 700 investments in six European economies and in high-potential countries around the world.

